Loriot Y, Sternberg CN, Castellano D, et al. - Researchers report outcomes of atezolizumab in a broader ‘real-world’ patient population with a history of autoimmune disease (AID) enrolled in the single-arm international SAUL study. Participants were patients with locally advanced/metastatic urinary tract carcinoma who were treated with atezolizumab 1200 mg every 3 weeks until loss of clinical advantage or unacceptable toxicity. As per findings, the observed incidences of special- interest and treatment-related adverse events (AEs) seemed acceptable in 35 atezolizumab-managed patients with pre-existing AID. The reported AEs were manageable, rarely necessitating atezolizumab discontinuation. Caution is needed to treat these patients, however, pre-existing AID does not preclude atezolizumab treatment.